Home How to Invest Your Account Performance Prospectus Reports About HY Bonds About Us	AHYFX Quote 800-528-3780
Performance
Net Asset Value as of March 12, 2010 NAV $10.57 Change $0.05 Percent Change 0.48% Average Annual Total Returns as of February 28, 2010   Aegis High Yield Fund Barclays® Capital High Yield Calendar Year-to-Date 2.55% 1.44% One Year 68.61% 56.26% Three Year 6.88% 5.60% Five Year 8.90% 6.48% Average Annual, Since Inception* 8.03% 7.28% Quarter-End Average Annual Total Returns as of December 31, 2009   Aegis High Yield Fund Barclays® Capital Calendar Year-to-Date 63.85% 58.21% One Year 63.85% 58.21% Three Year 7.29% 5.97% Five Year 8.60% 6.46% Average Annual, Since Inception* 7.80% 7.23%   * - Fund commenced operations January 1, 2004 Returns include reinvestment of dividends and capital gains. Performance data quoted represents past performance and does not guarantee future results. Current performance may be lower or higher than the performance data quoted. The investment return and principal value will fluctuate so that upon redemption, an investor’s shares may be worth more or less than their original cost. The Fund has an annualized expense ratio of 1.20% The Aegis Value Fund is offered by prospectus only. The investor should consider the Fund’s investment objectives, risks, charges, and expenses. The prospectus contains this and other information about the Fund. An investor can obtain a copy of the Fund's prospectus by downloading it from this website or by calling 1-800-528-3780. An investor should read the prospectus carefully before investing or sending money.
Date of First Use as Revised in Present Form 1/11/2008 Copyright © 2008 Aegis Financial Corporation. All Rights Reserved. Funds Distributed by Rafferty Capital Markets, LLC. www.aegisfunds.com Please consider the investment objectives, risks, charges and expenses of the Fund carefully before investing. View a prospectus containing this and call 800-528-3780. Please read the prospectus carefully before investing. View our Privacy Policy.